Hansa Biopharma secures $121m for kidney drug
Hansa Biopharma, the Swedish pharmaceuticals company, raised Skr1.1bn ($121m) through a sale of new shares on Wednesday evening to fund the launch of a new drug for patients undergoing kidney transplants.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: